Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Interrogation of a large clinical data cohort derived from a comprehensive panheme NGS-based assay for elucidation into MDS risk stratification, impact of chip on disease, biopsy sensitivity, and MRD evaluation

View Full Paper
Ask AI
Bookmark
Share

Authors

SGSean T. Glenn

Discussion

Loading...

Member takes

Overview

Comprehensive NGS assay shows improved disease monitoring in myeloid malignancies, indicating enhanced diagnostic capabilities.

Key Points

  • Genomic alterations identified in a large cohort have improved risk stratification for myeloid malignancies.
  • The comprehensive NGS assay promptly detects >46,000 unique mutations in hematological malignancies.
  • Observational analysis over 4,000 unique tests highlights diagnostic advancements and enhanced MDS monitoring.
  • Data analysis aids in understanding mutation roles in disease evolution and relapse potential.

Cite This Study

Sean T. Glenn (2025) studied this question.

synapsesocial.com/papers/69362f514fa91c937236d918https://doi.org/10.1182/blood-2025-7384
View Full Paper
Ask AI
Bookmark
Share